529 related articles for article (PubMed ID: 25519996)
21. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.
Messing EM; Manola J; Yao J; Kiernan M; Crawford D; Wilding G; di'SantAgnese PA; Trump D;
Lancet Oncol; 2006 Jun; 7(6):472-9. PubMed ID: 16750497
[TBL] [Abstract][Full Text] [Related]
22. Oncological Outcome of Cytoreductive Radical Prostatectomy in Prostate Cancer Patients With Bone Oligometastases.
Lan T; Chen Y; Su Q; Ye J
Urology; 2019 Sep; 131():166-175. PubMed ID: 31181273
[TBL] [Abstract][Full Text] [Related]
23. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
[TBL] [Abstract][Full Text] [Related]
24. Cytoreductive radical prostatectomy in metastatic prostate cancer: Does it really make sense?
Mathieu R; Korn SM; Bensalah K; Kramer G; Shariat SF
World J Urol; 2017 Apr; 35(4):567-577. PubMed ID: 27502935
[TBL] [Abstract][Full Text] [Related]
25. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
[TBL] [Abstract][Full Text] [Related]
26. Combination of adjuvant radiotherapy and androgen deprivation therapy after radical prostatectomy in high risk prostate cancer patients - results from retrospective analysis.
Omrcen T; Hrepic D; Boraska Jelavic T; Vrdoljak E
J BUON; 2015; 20(4):1061-7. PubMed ID: 26416057
[TBL] [Abstract][Full Text] [Related]
27. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
Prayer-Galetti T; Sacco E; Pagano F; Gardiman M; Cisternino A; Betto G; Sperandio P
BJU Int; 2007 Aug; 100(2):274-80. PubMed ID: 17355369
[TBL] [Abstract][Full Text] [Related]
28. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
[TBL] [Abstract][Full Text] [Related]
29. [Radical cancer surgery of renal cell and prostate carcinoma with hematogenous metastasis: benefits].
Heidenreich A; Pfister D; Porres D
Urologe A; 2014 Jun; 53(6):823-31. PubMed ID: 24824471
[TBL] [Abstract][Full Text] [Related]
30. Four prognostic indices in advanced prostate cancer patients, under palliative androgen deprivation treatment.
Bantis A; Zissimopoulos A; Kalaitzis C; Giannakopoulos S; Sountoulides P; Parmenopoulou V; Agelonidou E; Touloupidis S
Hell J Nucl Med; 2008; 11(1):21-5. PubMed ID: 18392222
[TBL] [Abstract][Full Text] [Related]
31. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
32. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
[TBL] [Abstract][Full Text] [Related]
33. Optimizing anti-androgen treatment use among men with pathologic lymph-node positive prostate cancer treated with radical prostatectomy: the importance of postoperative PSA kinetics.
Sood A; Zhang LT; Keeley J; Butaney M; Stricker M; Andrews JR; Grauer R; Peabody JO; Rogers CG; Menon M; Abdollah F
Prostate Cancer Prostatic Dis; 2024 Mar; 27(1):58-64. PubMed ID: 35794359
[TBL] [Abstract][Full Text] [Related]
34. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.
Asimakopoulos AD; Miano R; Virgili G; Vespasiani G; Finazzi Agrò E
Urol Oncol; 2012 Sep; 30(5):577-83. PubMed ID: 21292508
[TBL] [Abstract][Full Text] [Related]
35. Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy.
Hussain A; Wu Y; Mirmiran A; DiBiase S; Goloubeva O; Bridges B; Mannuel H; Engstrom C; Dawson N; Amin P; Kwok Y
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):167-74. PubMed ID: 21036487
[TBL] [Abstract][Full Text] [Related]
36. Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia.
Baade PD; Youlden DR; Gardiner RA; Ferguson M; Aitken JF; Yaxley J; Chambers SK
BJU Int; 2012 Dec; 110(11 Pt B):E712-9. PubMed ID: 23017157
[TBL] [Abstract][Full Text] [Related]
37. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.
Mottet N; Van Damme J; Loulidi S; Russel C; Leitenberger A; Wolff JM;
BJU Int; 2012 Nov; 110(9):1262-9. PubMed ID: 22502816
[TBL] [Abstract][Full Text] [Related]
38. The oncologic results of cryoablation in prostate cancer patients with bone metastases.
Si T; Guo Z; Yang X; Zhang W; Xing W
Int J Hyperthermia; 2018 Nov; 34(7):1044-1048. PubMed ID: 28974120
[TBL] [Abstract][Full Text] [Related]
39. Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy.
Yang DD; Muralidhar V; Mahal BA; Nezolosky MD; Labe SA; Vastola ME; Boldbaatar N; King MT; Martin NE; Orio PF; Choueiri TK; Trinh QD; Den RB; Spratt DE; Hoffman KE; Feng FY; Nguyen PL
Urol Oncol; 2017 Sep; 35(9):542.e25-542.e32. PubMed ID: 28533151
[TBL] [Abstract][Full Text] [Related]
40. [Androgen deprivation for advanced prostate cancer].
Heidenreich A; Pfister D; Ohlmann CH; Engelmann UH
Urologe A; 2008 Mar; 47(3):270-83. PubMed ID: 18273599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]